Debra Van Egeren

1.6k total citations · 1 hit paper
14 papers, 965 citations indexed

About

Debra Van Egeren is a scholar working on Infectious Diseases, Modeling and Simulation and Molecular Biology. According to data from OpenAlex, Debra Van Egeren has authored 14 papers receiving a total of 965 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 7 papers in Modeling and Simulation and 4 papers in Molecular Biology. Recurrent topics in Debra Van Egeren's work include COVID-19 epidemiological studies (7 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and Immunotherapy and Immune Responses (3 papers). Debra Van Egeren is often cited by papers focused on COVID-19 epidemiological studies (7 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and Immunotherapy and Immune Responses (3 papers). Debra Van Egeren collaborates with scholars based in United States, Australia and India. Debra Van Egeren's co-authors include Clara Park, Gregory L. Szeto, Darrell J. Irvine, Kelly D. Moynihan, Haipeng Liu, Bonnie Huang, Yiran Zheng, Arijit Chakravarty, Diane Joseph‐McCarthy and Michael S. Rogers and has published in prestigious journals such as Nature, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Debra Van Egeren

12 papers receiving 951 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structure-based programming of lymph-node targeting in molecular vaccines

2014 780 citations Haipeng Liu, Kelly D. Moynihan et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Debra Van Egeren United States	7	538	447	265	252	109	14	965
Lauren E. Milling United States	9	485 0.9×	257 0.6×	263 1.0×	238 0.9×	59 0.5×	11	787
Ben S. Ou United States	14	307 0.6×	325 0.7×	215 0.8×	144 0.6×	87 0.8×	20	776
Daniel Shae United States	9	848 1.6×	473 1.1×	377 1.4×	217 0.9×	174 1.6×	10	1.1k
Laura Jeanbart Switzerland	9	654 1.2×	399 0.9×	265 1.0×	372 1.5×	40 0.4×	10	1.0k
Gillie A. Roth United States	13	408 0.8×	343 0.8×	271 1.0×	170 0.7×	102 0.9×	20	1000
Sema Sevimli Australia	11	585 1.1×	403 0.9×	268 1.0×	133 0.5×	126 1.2×	12	930
Alex Schudel United States	11	541 1.0×	300 0.7×	264 1.0×	339 1.3×	51 0.5×	12	920
Marisa Aikins United States	10	296 0.6×	282 0.6×	253 1.0×	124 0.5×	81 0.7×	10	646
Sachin Bhagchandani United States	9	327 0.6×	276 0.6×	272 1.0×	119 0.5×	62 0.6×	11	865
Ans De Beuckelaer Belgium	13	369 0.7×	441 1.0×	166 0.6×	86 0.3×	106 1.0×	14	758

Countries citing papers authored by Debra Van Egeren

Since Specialization

Citations

This map shows the geographic impact of Debra Van Egeren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Van Egeren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Van Egeren more than expected).

Fields of papers citing papers by Debra Van Egeren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Van Egeren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Van Egeren. The network helps show where Debra Van Egeren may publish in the future.

Co-authorship network of co-authors of Debra Van Egeren

This figure shows the co-authorship network connecting the top 25 collaborators of Debra Van Egeren. A scholar is included among the top collaborators of Debra Van Egeren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra Van Egeren. Debra Van Egeren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Egeren, Debra Van, et al.. (2024). Looking under the lamp-post: quantifying the performance of contact tracing in the United States during the SARS-CoV-2 pandemic. BMC Public Health. 24(1). 595–595.

Egeren, Debra Van, et al.. (2024). Computational identification of antibody-binding epitopes from mimotope datasets. SHILAP Revista de lepidopterología. 4. 1295972–1295972.

Egeren, Debra Van, Laura F. White, Natasha S. Hochberg, et al.. (2023). Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2. Vaccines. 11(4). 853–853. 11 indexed citations

Egeren, Debra Van, Diane Joseph‐McCarthy, Laura F. White, et al.. (2022). No magic bullet: Limiting in-school transmission in the face of variable SARS-CoV-2 viral loads. Frontiers in Public Health. 10. 941773–941773. 3 indexed citations

Egeren, Debra Van, Laura F. White, Natasha S. Hochberg, et al.. (2022). Endemicity Is Not a Victory: The Unmitigated Downside Risks of Widespread SARS-CoV-2 Transmission. COVID. 2(12). 1689–1709. 2 indexed citations

Egeren, Debra Van, Bruce R. Zetter, Michael S. Rogers, et al.. (2021). Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS ONE. 16(4). e0250780–e0250780. 47 indexed citations

Egeren, Debra Van, et al.. (2021). Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis. PLoS ONE. 16(11). e0258997–e0258997. 6 indexed citations

Egeren, Debra Van, Shichen Liu, Maximilian Nguyen, et al.. (2021). Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Experimental Hematology. 107. 14–19. 8 indexed citations

Egeren, Debra Van, et al.. (2021). Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure. Scientific Reports. 11(1). 22630–22630. 13 indexed citations

10.

Egeren, Debra Van, et al.. (2021). Individually optimal choices can be collectively disastrous in COVID-19 disease control. BMC Public Health. 21(1). 832–832. 10 indexed citations

11.

Egeren, Debra Van, Thomas Madsen, & Franziska Michor. (2018). Fitness variation in isogenic populations leads to a novel evolutionary mechanism for crossing fitness valleys. Communications Biology. 1(1). 151–151. 4 indexed citations

12.

Szeto, Gregory L., Debra Van Egeren, Armon Sharei, et al.. (2015). Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines. Scientific Reports. 5(1). 10276–10276. 2 indexed citations

13.

Szeto, Gregory L., Debra Van Egeren, Armon Sharei, et al.. (2015). Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines. Europe PMC (PubMed Central). 79 indexed citations

14.

Liu, Haipeng, Kelly D. Moynihan, Yiran Zheng, et al.. (2014). Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 507(7493). 519–522. 780 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact